Abstract
Background Lack of functional evidence hampers variant interpretation, leaving a large proportion of cases with a suspected Mendelian disorder without genetic diagnosis after genome or whole exome sequencing (WES). Research studies advocate to further sequence transcriptomes to directly and systematically probe gene expression defects. However, collection of additional biopsies, and establishment of lab workflows, analytical pipelines, and defined concepts in clinical interpretation of aberrant gene expression are still needed for adopting RNA-sequencing (RNA-seq) in routine diagnostics.
Methods We implemented an automated RNA-seq protocol and a computational workflow with which we analyzed skin fibroblasts of 303 individuals with a suspected mitochondrial disease which previously underwent WES.
Results We detected on average 12,500 genes per sample including around 60% disease genes - a coverage substantially higher than with whole blood, supporting the use of skin biopsies. We prioritized genes demonstrating aberrant expression, aberrant splicing, or mono-allelic expression. The pipeline required less than one week from sample preparation to result reporting and provided a median of eight disease-associated genes per patient for inspection. A genetic diagnosis was established for 16% of the 205 WES-inconclusive cases. Detection of aberrant expression was a major contributor to diagnosis including instances of 50% reduction, which, together with mono-allelic expression, allowed for the diagnosis of dominant disorders caused by haploinsufficiency. Moreover, calling aberrant splicing and variants from RNA-seq data enabled detecting and validating splice-disrupting variants, of which the majority fell outside WES-covered regions.
Conclusion Together, these results show that streamlined experimental and computational processes can accelerate the implementation of RNA-seq in routine diagnostics.
One sentence summary Implementation of RNA-seq as a complementary tool in standard diagnostics achieves a 16% in diagnosis rate over whole exome sequencing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The German Bundesministerium fuer Bildung und Forschung (BMBF) supported the study through the ERA PerMed project PerMiM (01KU2016A to VAY, HP, and JG), the Medical Informatics Initiative CORD-MI (Collaboration on Rare Diseases) to VAY, the project MechML (01IS18053F to MM), the German Network for Mitochondrial Disorders (mitoNET; 01GM1113C to HP), and the E-Rare project GENOMIT (01GM1207 to HP). MG was supported by the DZHG (German Centre for Cardiovascular Research). This study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - NFDI 1/1 "GHGA - German Human Genome-Phenome Archive". The Bavaria California Technology Center supported CM through a fellowship. RWT is supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Lily Foundation and the UK NHS Specialised Commissioners who fund the "Rare Mitochondrial Disorders of Adults and Children" Service in Newcastle upon Tyne. CLA is supported by a National Institute for Health Research (NIHR) Post-Doctoral Fellowship (PDF-2018-11-ST2-021). This work was supported by the Practical Research Project for Rare/Intractable Diseases (JP20ek0109468, JP19ek0109273) from the Agency for Medical Research and Development (AMED), Japan. This research was supported by the Instituto de Salud Carlos III (PI16/01048; PI19/01310) (Co-funded by European Regional Development Fund "A way to make Europe") and the Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), an initiative of the Instituto de Salud Carlos III (Ministerio de Ciencia e Innovacion, Spain). The present study was supported by the Departament de Salut, Generalitat de Catalunya (URDCAT project, SLT002/16/00174). This study was supported by the Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) (2017: SGR 1428) and the CERCA Programme/Generalitat de Catalunya. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx Portal on June 12, 2017, under accession number dbGaP: phs00424.v6.p1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All individuals included or their legal guardians provided written informed consent before evaluation, in agreement with the Declaration of Helsinki and approved by the ethical committees of the centers participating in this study. All studies were completed according to local approval of the ethical committee of the Technical University of Munich.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated format to fit a new journal. Authors updated.
Data Availability
Privacy-preserving count matrices are publicly available without restriction through Zenodo: 10.5281/zenodo.4646823 and 10.5281/zenodo.4646827. Due to data privacy policy, we cannot provide BAM or VCF files.
- Abbreviations
- CAT
- Clinically accessible tissue
- EBV
- Epstein-Barr virus
- FDR
- False discovery rate
- LoF
- Loss-of-function
- MAE
- Mono-allelic expression
- MNV
- Multi-nucleotide variant
- mtDNA
- Mitochondrial DNA
- NBPF
- Neuroblastoma breakpoint family
- NGS
- Next generation sequencing
- NMD
- Nonsense-mediated decay
- PTC
- Premature termination codon
- PTV
- Protein-truncating variant
- RNA-seq
- RNA sequencing
- SNV
- Single nucleotide variant
- UTR
- Untranslated region
- VEP
- Variant effect predictor
- VUS
- Variant of uncertain significance
- WES
- Whole exome sequencing
- WGS
- Whole genome sequencing
